静脉滴注异麦芽糖酐铁治疗缺铁性贫血的疗效及安全性评估:单中心回顾性分析  

Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia:a single-center retrospective analysis

作　　者：丁少雪[1] 赵伊慧 王婷[1] 关晶[1] 邢莉民[1] 刘鸿[1] 王国锦[1] 王晓明[1] 吴玉红[1] 瞿文[1] 宋嘉[1] 王化泉[1] 李丽娟[1] 邵宗鸿[1] 付蓉[1] Ding Shaoxue;Zhao Yihui;Wang Ting;Guan Jing;Xing Limin;Liu Hong;Wang Guojin;Wang Xiaoming;Wu Yuhong;Qu Wen;Song Jia;Wang Huaquan;Li Lijuan;Shao Zonghong;Fu Rong(Department of Hematology,Tianjin Medical University General Hospital,Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院血液内科,天津市骨髓衰竭及癌性造血克隆防治重点实验室,天津300052

出　　处：《中华血液学杂志》2024年第2期178-183,共6页Chinese Journal of Hematology

基　　金：国家自然科学基金面上项目(82270142);天津市医学重点学科(专科)建设项目(TJYXZDXK-028A);白求恩公益基金会-医学研究项目(HXJH-2022-02)。

摘　　要：目的探讨缺铁性贫血(IDA)患者应用异麦芽糖酐铁注射液对比蔗糖铁注射液治疗的临床疗效及安全性。方法选取2021年6月至2023年3月期间收治的缺铁性贫血患者120例,应用异麦芽糖酐铁注射液静脉补铁治疗,观察患者治疗前后HGB提升的有效性和安全性。同时与同期病房应用蔗糖铁补铁患者临床疗效及安全性进行对比。结果两组患者基线HGB相当。治疗12周内,异麦芽糖酐铁组提升HGB水平高于蔗糖铁,各个时间差异均具有统计学意义(均P<0.01),治疗4周患者HGB提升超过20g/L比例更高(98.7%对75.9%)。治疗过程中,异麦芽糖酐铁组发生轻度不良反应比例略低于蔗糖铁组,两组均无严重不良输液反应发生,输注治疗过程中患者耐受性良好,无注射部位疼痛及色素沉着等不良反应。结论IDA患者应用异麦芽糖酐铁治疗疗效满意,具有见效迅速、疗效确切、安全性高的优点,值得临床广泛应用。Objective To investigate the clinical efficacy and safety of ferric derisomaltose injection versus iron sucrose injection in the treatment of iron deficiency anemia(IDA).Methods A total of 120 patients with iron deficiency anemia admitted from June 2021 to March 2023 were given intravenous iron supplementation with ferric derisomaltose to assess the efficacy and safety of hemoglobin(HGB)elevation before and after treatment.Simultaneously,the clinical effects of iron supplementation with iron sucrose were compared to those of inpatient patients during the same period.Results Baseline values were comparable in both groups.Within 12 weeks of treatment,the elevated HGB level in the ferric derisomaltose group was higher than that of the iron sucrose group,with a statistical difference at all time points,and the proportion of HGB increased over 20 g/L in the patients treated for 4 weeks was higher(98.7%,75.9%).During the treatment with ferric derisomaltose and iron sucrose,the proportion of mild adverse reactions in the ferric derisomaltose group was slightly lower than that of the iron sucrose group,and neither group experienced any serious adverse reactions.The patients responded well to the infusion treatment,with no reports of pain or pigmentation at the injection site.Conclusion The treatment of IDA patients with ferric derisomaltose has a satisfactory curative effect,with the advantages of rapidity,accuracy,and safety.Therefore,it is worthy of widespread clinical use.

关 键 词：缺铁性贫血 静脉异麦芽糖酐铁 静脉蔗糖铁 

分 类 号：R556.3[医药卫生—血液循环系统疾病]